Updated Interim Results Show Prolonged Survival and Immune Activation in Borderline Resectable PDAC Patients
Candel Therapeutics (CADL), a clinical-stage biopharmaceutical company focused on innovative cancer immunotherapies, unveiled promising interim survival data from its ongoing phase 2 trial of CAN-2409 for pancreatic ductal adenocarcinoma (PDAC). The updated findings, presented by Chief Medical Officer Garrett Nichols, MD, MS, at the 2024 data cut-off, showcase significant improvements in overall survival and immune activation.
Patients treated with CAN-2409 plus valacyclovir, alongside standard chemoradiation, exhibited a median overall survival of 28.8 months, compared to 12.5 months in the control group. Notably, survival rates at 24 and 36 months were substantially higher in the CAN-2409 cohort, indicating durable benefits.
Furthermore, analyses of resected tumors revealed dense aggregates of immune cells, suggestive of robust antitumoral immune responses. The treatment’s safety profile remained favorable, with no dose-limiting toxicities observed.
Paul Peter Tak, MD, PhD, President and CEO of Candel, expressed optimism about CAN-2409’s potential to reshape the pancreatic cancer treatment landscape by modulating the tumor microenvironment and enhancing immune responses. These findings underscore the promise of CAN-2409 as a transformative therapy for patients with PDAC.
Read original press release:here
You might like this article:Tesla Explores India for $2-3 Billion Electric Car Plant
